Řecko - řečtina - Εθνικός Οργανισμός Φαρμάκων

ΦΑΡΜΑΣΕΡΒ ΛΙΛΛΥ Α.Ε.Β.Ε. 15ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας,, 145 64 145 64, Κηφισιά 6294600, 6294822 - atomoxetine hydrochloride - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 25mg/cap - atomoxetine hydrochloride 28,57mg - atomoxetine

Belgie - němčina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eli lilly benelux - atomoxetine hydrochloride - hartkapsel - 25 mg - atomoxetine hydrochloride 28.57 mg - atomoxetine

Nizozemsko - nizozemština - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eli lilly nederland b.v. papendorpseweg 83 3528 bj utrecht - atomoxetinehydrochloride samenstelling overeenkomend met ; atomoxetine - capsule, hard - ammonia (e 527) ; dimeticon (e 900) ; gelatine (e 441) ; ijzeroxide zwart (e 172) ; indigokarmijn (e 132) ; kaliumhydroxide (e 525) ; natriumlaurilsulfaat (e 487) ; propyleenglycol (e 1520) ; schellak (e 904) ; titaandioxide (e 171) ; zetmeel, gepregelatineerd ; zwarte inkt, - atomoxetine

Rakousko - němčina - AGES (Agentur für Gesundheit und Ernährungssicherheit)

eli lilly ges.m.b.h. - atomoxetin hydrochlorid - atomoxetin

Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

abacus medicine a/s - atomoxetinhydrochlorid - kapsler, hårde - 25 mg

Malta - angličtina - Malta Medicines Authority

eli lilly & co. limited - atomoxetine - hard capsule - atomoxetine 25 mg - psychoanaleptics

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - atomoxetine hydrochloride - capsule, hard - 25 milligram(s) - centrally acting sympathomimetics; atomoxetine

Jihoafrická republika - angličtina - South African Health Products Regulatory Authority (SAHPRA)

eli lilly (s.a.) (pty) ltd - capsules - see ingredients - each capsule contains atomoxetine hydrochloride equivalent to atomoxetine 25,0 mg

Spojené arabské emiráty - angličtina - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmatrade spain - 28's (7's blister x 4) - capsule - 25mg / capsule - central nervous system-psychoses , related disorders

Spojené státy - angličtina - NLM (National Library of Medicine)

eli lilly and company - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 10 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see clinical studies (14)] . a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of adhd is unknown, and there is no single diagnostic test. adequate diagnosis r